ATE256131T1 - Calanolide zur hemmung von btk - Google Patents
Calanolide zur hemmung von btkInfo
- Publication number
- ATE256131T1 ATE256131T1 AT00916367T AT00916367T ATE256131T1 AT E256131 T1 ATE256131 T1 AT E256131T1 AT 00916367 T AT00916367 T AT 00916367T AT 00916367 T AT00916367 T AT 00916367T AT E256131 T1 ATE256131 T1 AT E256131T1
- Authority
- AT
- Austria
- Prior art keywords
- calanolides
- inhibiting btk
- calanolide
- tec family
- btk inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12603999P | 1999-03-19 | 1999-03-19 | |
| US09/354,550 US6306897B1 (en) | 1999-03-19 | 1999-07-15 | Calanolides for inhibiting BTK |
| PCT/US2000/006805 WO2000056737A2 (en) | 1999-03-19 | 2000-03-16 | Calanolides for inhibiting btk |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE256131T1 true ATE256131T1 (de) | 2003-12-15 |
Family
ID=26824213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00916367T ATE256131T1 (de) | 1999-03-19 | 2000-03-16 | Calanolide zur hemmung von btk |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6306897B1 (de) |
| EP (1) | EP1163243B1 (de) |
| JP (1) | JP2003528801A (de) |
| AT (1) | ATE256131T1 (de) |
| AU (1) | AU3748000A (de) |
| CA (1) | CA2365244A1 (de) |
| DE (1) | DE60007095T2 (de) |
| WO (1) | WO2000056737A2 (de) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2390857A1 (en) * | 1999-11-30 | 2001-06-14 | Fatih M. Uckun | Inhibitors of collagen-induced platelet aggregation |
| US6589992B2 (en) | 1999-11-30 | 2003-07-08 | Parker Hughes Institute | Inhibiting collagen-induced platelet aggregation |
| GB0005345D0 (en) * | 2000-03-06 | 2000-04-26 | Mathilda & Terence Kennedy Ins | Methods of treating sepsis septic shock and inflammation |
| CA2426508A1 (en) * | 2000-10-23 | 2002-05-16 | Bristol-Myers Squibb Company | Modulators of bruton's tyrosine kinase and bruton's tyrosine kinase intermediates and methods for their identification and use in the treatment and prevention of osteoporosis and related disease states |
| WO2003016338A1 (en) * | 2001-08-15 | 2003-02-27 | Parker Hughes Institute | Crystal structure of the btk kinase domain |
| AU2002360519B2 (en) * | 2001-12-07 | 2008-09-25 | University Of Wyoming | Methods and compositions for the diagnosis of asthma |
| WO2004066994A1 (ja) * | 2003-01-28 | 2004-08-12 | Kansai Technology Licensing Organization Co. Ltd. | 抗癌剤 |
| EP1831168B1 (de) * | 2004-12-16 | 2014-07-02 | Vertex Pharmaceuticals Inc. | Als inhibitoren der proteinkinasen der tec-familie geeignete pyrid-2-one zur behandlung entzündlicher, proliferativer und immunologisch vermittelter krankheiten |
| RU2008133161A (ru) | 2006-01-13 | 2010-02-20 | Фармасайкликс, Инк. (Us) | Ингибиторы тирозин киназ и их применение |
| EA018573B1 (ru) | 2006-09-22 | 2013-09-30 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
| US8809273B2 (en) | 2007-03-28 | 2014-08-19 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
| EP2205564B1 (de) * | 2007-10-23 | 2014-07-30 | F. Hoffmann-La Roche AG | Neue kinaseinhibitoren |
| JP5479105B2 (ja) * | 2007-11-05 | 2014-04-23 | 国立大学法人佐賀大学 | 新規ユビキリン結合性小分子 |
| US7932036B1 (en) | 2008-03-12 | 2011-04-26 | Veridex, Llc | Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase |
| CN105362277A (zh) | 2008-07-16 | 2016-03-02 | 药品循环有限公司 | 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂 |
| CA3007787C (en) | 2010-06-03 | 2020-03-10 | Pharmacyclics Llc | The use of inhibitors of bruton's tyrosine kinase (btk) |
| CA2806112C (en) | 2010-07-28 | 2023-03-21 | Veridex, Llc | Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors |
| BR112014000653A2 (pt) | 2011-07-13 | 2017-02-14 | Pharmacyclics Inc | inibidores de tirosina quinase de bruton |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| EA201492082A1 (ru) | 2012-06-04 | 2015-03-31 | Фармасайкликс, Инк. | Кристаллические формы ингибитора тирозинкиназы брутона |
| CA2879570A1 (en) | 2012-07-24 | 2014-01-30 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
| MX2015006168A (es) | 2012-11-15 | 2015-08-10 | Pharmacyclics Inc | Compuestos de pirrolopirimidina como inhibidores de quinasas. |
| CA2938626A1 (en) | 2013-07-26 | 2015-01-29 | John Rothman | Compositions to improve the therapeutic benefit of bisantrene |
| TWI649081B (zh) | 2013-08-02 | 2019-02-01 | 製藥公司 | 治療固態腫瘤之方法 |
| ES2709509T3 (es) | 2013-08-12 | 2019-04-16 | Pharmacyclics Llc | Procedimientos para el tratamiento de cáncer amplificado por HER2 |
| KR20160062103A (ko) | 2013-09-30 | 2016-06-01 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 키나제의 억제제 |
| EP3060218A4 (de) | 2013-10-25 | 2017-07-19 | Pharmacyclics LLC | Verfahren zur behandlung und prävention von transplantatabstossung |
| US9908872B2 (en) | 2013-12-13 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| JP6879740B2 (ja) | 2013-12-13 | 2021-06-02 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | リンパ形質細胞性リンパ腫を処置する方法 |
| EP3119910A4 (de) | 2014-03-20 | 2018-02-21 | Pharmacyclics LLC | Phospholipase c gamma 2 und resistenzassoziierte mutationen |
| CN106999494A (zh) | 2014-08-01 | 2017-08-01 | 药品循环有限公司 | 布鲁顿酪氨酸激酶的抑制剂 |
| JP2017523206A (ja) | 2014-08-07 | 2017-08-17 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼ阻害剤の新規製剤 |
| JP6788583B2 (ja) | 2014-10-22 | 2020-11-25 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 増殖性疾患を処置するためのチアゾリル含有化合物 |
| IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibitor |
| US20250241918A1 (en) * | 2022-04-12 | 2025-07-31 | Hefei Youyuan Pharmaceutical Co., Ltd. | Novel use of pyrazolopyrimidine compound |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| WO1994014789A1 (en) | 1992-12-23 | 1994-07-07 | Smithkline Beecham Corporation | Coumarin derivatives as retroviral inhibitors |
| US5489697A (en) | 1994-08-03 | 1996-02-06 | Medichem Research, Inc. | Method for the preparation of (+)-calanolide A and intermediates thereof |
| CA2328962A1 (en) | 1998-04-17 | 1999-10-28 | Parker Hughes Institute | Btk inhibitors and methods for their identification and use |
-
1999
- 1999-07-15 US US09/354,550 patent/US6306897B1/en not_active Expired - Fee Related
-
2000
- 2000-03-16 EP EP00916367A patent/EP1163243B1/de not_active Expired - Lifetime
- 2000-03-16 JP JP2000606598A patent/JP2003528801A/ja not_active Withdrawn
- 2000-03-16 CA CA002365244A patent/CA2365244A1/en not_active Abandoned
- 2000-03-16 AT AT00916367T patent/ATE256131T1/de not_active IP Right Cessation
- 2000-03-16 AU AU37480/00A patent/AU3748000A/en not_active Abandoned
- 2000-03-16 DE DE60007095T patent/DE60007095T2/de not_active Expired - Fee Related
- 2000-03-16 WO PCT/US2000/006805 patent/WO2000056737A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DE60007095T2 (de) | 2004-10-07 |
| AU3748000A (en) | 2000-10-09 |
| CA2365244A1 (en) | 2000-09-28 |
| WO2000056737A2 (en) | 2000-09-28 |
| US6306897B1 (en) | 2001-10-23 |
| JP2003528801A (ja) | 2003-09-30 |
| EP1163243B1 (de) | 2003-12-10 |
| WO2000056737A3 (en) | 2001-02-08 |
| DE60007095D1 (de) | 2004-01-22 |
| EP1163243A2 (de) | 2001-12-19 |
| WO2000056737A9 (en) | 2001-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE256131T1 (de) | Calanolide zur hemmung von btk | |
| NO20005224D0 (no) | BTK inhibitorer og fremgangsmÕter for deres identifikasjon og anvendelse | |
| CY1105349T1 (el) | Θειαζολυλ-αναστολεις τυροκινασεων της οικογενειας tec | |
| ATE455092T1 (de) | Substituierte tetracyclin-verbindungen zur behandlung von malaria | |
| EA200601555A1 (ru) | Замещенные индазол-о-глюкозиды | |
| TW200508214A (en) | Novel compounds | |
| CA2366932A1 (en) | Cyclic protein tyrosine kinase inhibitors | |
| EA200601554A1 (ru) | Замещенные индол-о-глюкозиды | |
| ATE267830T1 (de) | Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen | |
| AR024138A1 (es) | Inhibidores de la proliferacion celular | |
| SE0104251D0 (sv) | Novel compounds | |
| DE10082139T1 (de) | Zusammensetzung zur Behandlung von Reibungspaaren | |
| PL1654253T3 (pl) | Podstawione pochodne 3-pirolidynoindolu | |
| BR0114903A (pt) | 7-azaindóis, sua aplicação como inibidores da fosfodiesterase 4 e processos para a sua preparação | |
| DE60105025D1 (de) | Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie | |
| SE9904377D0 (sv) | Pharmaceutical combinations | |
| SE9802937D0 (sv) | Novel compounds | |
| BRPI0515721A (pt) | uso de um inibidor de src cinase e um inibidor de bcr-abl, composição farmacêutica e combinação | |
| SE0301650D0 (sv) | Novel compounds | |
| DE602004032465D1 (de) | Referenzstandard zur charakterisierung von rosuvastatin | |
| ITSV20030016A1 (it) | Sostanze contenenti tannini o miscele di tannini. | |
| UY28685A1 (es) | Heterociclos con contenido de nitrógeno que afectan la transmisión sináptica glutamatérgica | |
| NO20033921L (no) | Inhibitor av monoaminopptak | |
| BRPI0417263A (pt) | imidazopiridinas para uso como inibidores de secreção gástrica | |
| ATE460168T1 (de) | Nicht-radioaktives strontiummittel zur behandlung von krebs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |